Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
Noosa News16 hours agoJazz sellout at The J
-
General15 hours agoAnne-Marie Te Whiu on new book of poetry, Mettle, and why she dedicated it to her younger self
-
Noosa News12 hours agoMigration blunders lead to strike-off – Proctor
-
Business9 hours agoGold price alert! Macquarie reveals its top ASX 200 gold stock as the metal hits all-time high